---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124636"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:20:39.830529+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CG Oncology Q3 net loss $20.4M; cash $540.7M, runway through 2027

## Summary
- Net loss of $20.4M ($0.30 per share) vs $17.5M ($4.00) in Q3 2023.
- Cash and securities $540.7M as of Sept 30, 2024; expects to fund operations through 2027.
- R&D expenses $19.6M (up from $11.7M) driven by clinical trial and CMC costs.
- G&A expenses $8.7M (up from $2.3M) due to personnel, professional fees, insurance.
- Phase 3 BOND-003 cretostimogene results accepted as late-breaking abstract at SUO 2024.

## SEC filing metadata
- accession: 0000950170-24-124636
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000095017024124636/0000950170-24-124636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000095017024124636/ck0001991792-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124636
- JSON: https://secwatch.observer/filing/0000950170-24-124636.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124636.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.